These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37893542)

  • 21. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis.
    Verpoort KN; van Gaalen FA; van der Helm-van Mil AH; Schreuder GM; Breedveld FC; Huizinga TW; de Vries RR; Toes RE
    Arthritis Rheum; 2005 Oct; 52(10):3058-62. PubMed ID: 16200610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VEGF Gene Polymorphisms Affect Serum Protein Levels and Alter Disease Activity and Synovial Lesions in Rheumatoid Arthritis.
    Yi JP; Wu YZ; Yu N; Yu ZW; Xie FY; Yuan Q
    Med Sci Monit; 2016 Jan; 22():316-24. PubMed ID: 26825024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-cyclic citrullinated peptide antibodies--activity markers in rheumatoid arthritis.
    Predeteanu D; Varzaru L; Balanescu A; Bojinca V; Opris D; Vlad V; Berghea F; Abobului M; Constantinescu C; Ionescu R
    J Med Life; 2009; 2(1):36-41. PubMed ID: 20108489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years.
    da Mota LM; Dos Santos Neto LL; de Carvalho JF; Pereira IA; Burlingame R; Ménard HA; Laurindo IM
    Rheumatol Int; 2012 Dec; 32(12):3807-12. PubMed ID: 22187055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
    Chang PY; Yang CT; Cheng CH; Yu KH
    Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis.
    Mjaavatten MD; van der Heijde D; Uhlig T; Haugen AJ; Nygaard H; Sidenvall G; Helgetveit K; Kvien TK
    Arthritis Res Ther; 2010; 12(3):R76. PubMed ID: 20444271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of third generation anti-CCP antibodies in the diagnosis of rheumatoid arthritis from undifferentiated polyarthritis after 4 years of follow-up.
    Caro-Oleas JL; Fernández-Suárez A; Reneses Cesteros S; Porrino C; Núñez-Roldán A; Wichmann Schlipf I
    Clin Exp Rheumatol; 2008; 26(3):461-3. PubMed ID: 18578970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of anti-citrullinated protein antibodies and rheumatoid factor is associated with increased systemic inflammatory mediators and more rapid progression from preclinical to clinical rheumatoid arthritis.
    Lingampalli N; Sokolove J; Lahey LJ; Edison JD; Gilliland WR; Holers VM; Deane KD; Robinson WH
    Clin Immunol; 2018 Oct; 195():119-126. PubMed ID: 29842946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis.
    Hiura K; Iwaki-Egawa S; Kawashima T; Fujisawa S; Takeda T; Komori H; Watanabe Y
    Rheumatol Int; 2013 Sep; 33(9):2309-14. PubMed ID: 23503938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study.
    Alemao E; Guo Z; Frits ML; Iannaccone CK; Shadick NA; Weinblatt ME
    Semin Arthritis Rheum; 2018 Apr; 47(5):630-638. PubMed ID: 29241640
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Guzmán-Guzmán IP; Ramírez-Vélez CI; Falfán-Valencia R; Navarro-Zarza JE; Gutiérrez-Pérez IA; Zaragoza-García O; Ramírez M; Castro-Alarcón N; Parra-Rojas I
    Front Immunol; 2021; 12():718246. PubMed ID: 34421923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes with HLA-DRB1 shared epitope alleles in Egyptian rheumatoid arthritis patients.
    Raslan HM; Attia HR; Hamed Ibrahim M; Mahmoud Hassan E; Salama II; Ismail S; Abdelmotaleb E; El Menyawi MM; Amr KS
    Int J Rheum Dis; 2020 May; 23(5):647-653. PubMed ID: 32167241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy and tolerability of self-sampling of capillary blood for analysis of inflammation and autoantibodies in rheumatoid arthritis patients-results from a randomized controlled trial.
    Knitza J; Tascilar K; Vuillerme N; Eimer E; Matusewicz P; Corte G; Schuster L; Aubourg T; Bendzuck G; Korinth M; Elling-Audersch C; Kleyer A; Boeltz S; Hueber AJ; Krönke G; Schett G; Simon D
    Arthritis Res Ther; 2022 May; 24(1):125. PubMed ID: 35614488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-15 as a Biomarker Candidate of Rheumatoid Arthritis Development.
    Kurowska W; Przygodzka M; Jakubaszek M; Kwiatkowska B; Maslinski W
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32455601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis.
    Li C; Zhang Y; Song H; Gao J; Zhao DB; Zhu Q; He DY; Wang L; Li XP; Liu XD; Xiao WG; Wu XY; Wu HX; Tu W; Hu SX; Wang X; Li ZJ; Lu ZM; Da ZY; Liang B; Liu XM; Zhao JW; Li L; Han F; Qi WF; Wei W; Ma X; Li ZB; Zheng GM; Zhang FX; Li Y; Wang YL; Ling GH; Chen JW; Hou XQ; Zhang J; Chen QP; Liu CL; Zhang Y; Zeng JS; Zou QH; Fang YF; Su Y; Li ZG
    Chin Med J (Engl); 2019 Dec; 132(24):2899-2904. PubMed ID: 31855969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
    Nell VP; Machold KP; Stamm TA; Eberl G; Heinzl H; Uffmann M; Smolen JS; Steiner G
    Ann Rheum Dis; 2005 Dec; 64(12):1731-6. PubMed ID: 15878904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations of HLA-DRB1 alleles with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in northern east part of Turkey.
    Uçar F; Çapkin E; Karkucak M; Yücel B; Sönmez M; Alver A; Kaklikkaya N; Tosun M; Alemdaroğlu E; Solak M
    Int J Rheum Dis; 2012 Dec; 15(6):538-45. PubMed ID: 23253237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and predictive value of anti-cyclic citrullinated protein antibodies for future development of rheumatoid arthritis in early undifferentiated arthritis.
    Emad Y; Shehata M; Ragab Y; Saad A; Hamza H; Abou-Zeid A
    Mod Rheumatol; 2010 Aug; 20(4):358-65. PubMed ID: 20364358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.